Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
paclitaxel + gemcitabine + sunitinib
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Paclitaxel + gemcitabine + sunitinib is a combination regimen of three anticancer agents used in investigational settings for the treatment of advanced solid tumors. Paclitaxel is a microtubule-stabilizing agent that inhibits cell division, gemcitabine is a nucleoside analog that inhibits DNA synthesis, and sunitinib is an oral small-molecule multi-targeted receptor tyrosine kinase inhibitor targeting VEGF receptors, PDGF receptors, KIT, FLT3, CSF-1R, and RET. The combination aims to leverage cytotoxic effects (from paclitaxel and gemcitabine) with antiangiogenic and antiproliferative activity (from sunitinib), potentially enhancing antitumor efficacy compared to single-agent or doublet regimens. This regimen has been studied in early-phase clinical trials for various advanced solid tumors including pancreatic cancer, renal cell carcinoma, breast cancer, non-small-cell lung cancer (NSCLC), and others[1][2][6].
- Brand names
- Abraxane
- Other names
- GemTaxol
02
Targets
KIT (c-KIT proto-oncogene receptor tyrosine kinase)VEGFR2 (Vascular endothelial growth factor receptor 2)PDGFRA (Platelet-derived growth factor receptor alpha)RET (Rearranged during transfection receptor tyrosine kinase)VEGFR-1 (Vascular endothelial growth factor receptor 1)DNATUBB (Tubulin (alpha and beta subunits))PDGFRB (Platelet-derived growth factor receptor beta)CSF1R (Macrophage colony-stimulating factor receptor)VEGFR3 (Vascular endothelial growth factor receptor 3)FLT3 (Fms related receptor tyrosine kinase 3)RRM1
Beyond the preview
Go deeper on paclitaxel + gemcitabine + sunitinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on paclitaxel + gemcitabine + sunitinib.